Toshio Miyata

机构：Tohoku University · ORCID：0000-0001-9153-5024

发表论文 452 篇 · 总被引 22563 次 · h-index 83

代表论文

• Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1 (2024 · Frontiers in Immunology · 被引 44)
• A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial (2024 · British Journal of Dermatology · 被引 28)
• A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19 (2024 · Scientific Reports · 被引 18)
• Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol (2023 · Experimental Dermatology · 被引 16)
• Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer (2024 · Journal of Thoracic Disease · 被引 13)
• PAI-1 is a common driver of aging and diverse diseases (2025 · Biomedical Journal · 被引 11)